Cargando…

Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy—An Overview

Topoisomerase (Topo) inhibitors have long been known as clinically effective drugs, while G-quadruplex (G4)-targeting compounds are emerging as a promising new strategy to target tumor cells and could support personalized treatment approaches in the near future. G-quadruplex (G4) is a secondary four...

Descripción completa

Detalles Bibliográficos
Autores principales: Salerno, Silvia, Barresi, Elisabetta, Baglini, Emma, Poggetti, Valeria, Taliani, Sabrina, Da Settimo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687504/
https://www.ncbi.nlm.nih.gov/pubmed/36428499
http://dx.doi.org/10.3390/biomedicines10112932
_version_ 1784836022087974912
author Salerno, Silvia
Barresi, Elisabetta
Baglini, Emma
Poggetti, Valeria
Taliani, Sabrina
Da Settimo, Federico
author_facet Salerno, Silvia
Barresi, Elisabetta
Baglini, Emma
Poggetti, Valeria
Taliani, Sabrina
Da Settimo, Federico
author_sort Salerno, Silvia
collection PubMed
description Topoisomerase (Topo) inhibitors have long been known as clinically effective drugs, while G-quadruplex (G4)-targeting compounds are emerging as a promising new strategy to target tumor cells and could support personalized treatment approaches in the near future. G-quadruplex (G4) is a secondary four-stranded DNA helical structure constituted of guanine-rich nucleic acids, and its stabilization impairs telomere replication, triggering the activation of several protein factors at telomere levels, including Topos. Thus, the pharmacological intervention through the simultaneous G4 stabilization and Topos inhibition offers a new opportunity to achieve greater antiproliferative activity and circumvent cellular insensitivity and resistance. In this line, dual ligands targeting both Topos and G4 emerge as innovative, efficient agents in cancer therapy. Although the research in this field is still limited, to date, some chemotypes have been identified, showing this dual activity and an interesting pharmacological profile. This paper reviews the available literature on dual Topo inhibitors/G4 stabilizing agents, with particular attention to the structure–activity relationship studies correlating the dual activity with the cytotoxic activity.
format Online
Article
Text
id pubmed-9687504
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96875042022-11-25 Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy—An Overview Salerno, Silvia Barresi, Elisabetta Baglini, Emma Poggetti, Valeria Taliani, Sabrina Da Settimo, Federico Biomedicines Review Topoisomerase (Topo) inhibitors have long been known as clinically effective drugs, while G-quadruplex (G4)-targeting compounds are emerging as a promising new strategy to target tumor cells and could support personalized treatment approaches in the near future. G-quadruplex (G4) is a secondary four-stranded DNA helical structure constituted of guanine-rich nucleic acids, and its stabilization impairs telomere replication, triggering the activation of several protein factors at telomere levels, including Topos. Thus, the pharmacological intervention through the simultaneous G4 stabilization and Topos inhibition offers a new opportunity to achieve greater antiproliferative activity and circumvent cellular insensitivity and resistance. In this line, dual ligands targeting both Topos and G4 emerge as innovative, efficient agents in cancer therapy. Although the research in this field is still limited, to date, some chemotypes have been identified, showing this dual activity and an interesting pharmacological profile. This paper reviews the available literature on dual Topo inhibitors/G4 stabilizing agents, with particular attention to the structure–activity relationship studies correlating the dual activity with the cytotoxic activity. MDPI 2022-11-15 /pmc/articles/PMC9687504/ /pubmed/36428499 http://dx.doi.org/10.3390/biomedicines10112932 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Salerno, Silvia
Barresi, Elisabetta
Baglini, Emma
Poggetti, Valeria
Taliani, Sabrina
Da Settimo, Federico
Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy—An Overview
title Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy—An Overview
title_full Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy—An Overview
title_fullStr Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy—An Overview
title_full_unstemmed Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy—An Overview
title_short Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy—An Overview
title_sort dual targeting topoisomerase/g-quadruplex agents in cancer therapy—an overview
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687504/
https://www.ncbi.nlm.nih.gov/pubmed/36428499
http://dx.doi.org/10.3390/biomedicines10112932
work_keys_str_mv AT salernosilvia dualtargetingtopoisomerasegquadruplexagentsincancertherapyanoverview
AT barresielisabetta dualtargetingtopoisomerasegquadruplexagentsincancertherapyanoverview
AT bagliniemma dualtargetingtopoisomerasegquadruplexagentsincancertherapyanoverview
AT poggettivaleria dualtargetingtopoisomerasegquadruplexagentsincancertherapyanoverview
AT talianisabrina dualtargetingtopoisomerasegquadruplexagentsincancertherapyanoverview
AT dasettimofederico dualtargetingtopoisomerasegquadruplexagentsincancertherapyanoverview